Таргетная терапия больных истинной полицитемией
PDF

Ключевые слова

истинная полицитемия
мутация в гене Янус киназы 2 (JAK2)
таргетная терапия
ингибиторы JAK2
руксолитиниб

Аннотация

Открытие мутации JAK2V617F явилось началом новой эры в изучеНИИ миелопролиферативных неоплазий (МGY). помимо вклада в понимание патофизиологии Ph-негативных МGY, мутация JAK2 стала новой терапевтической мишенью в их лечении. В лечении BG началась новая эра таргетной терапии, которая дает надежду на лучшие результаты лечения и улучшения качества жизни пациентам, резистентным к стандартной терапии. В работе представлены литературные данные о молекулярно-генетических особенностях патогенеза истинной полицитемии (ИП) и новых возможностях в лечении данного заболевания, литературный обзор об ингибиторах янускиназ, таргетной терапии ип. рассмотрены вопросы резистенности и непереностимости терапии гидроксикарбамидом и препаратами интерферона(IFN-α), а также определения показаний к назначению ингибиторов янускиназ. представлены данные об эффективности и безопасности руксолитиниба, доказанные в рамках клинического исследования RESPONSE.
https://doi.org/10.18722/VO2016624386-393
PDF

Литература

Гусева С. А., Бессмельцев С. С., Абдулкадыров К. М., Гончаров Я. П. Истинная полицитемия. 2009. - Киев. -СПб: Логос. 405 с.

демидова А. В., К. Н. Н., Мазуров В. И., Эритремия и вторичные эритроцитозы 2001. - СПб: изд-во СПбМА-ПО. 228 с.

Alessandro M. Vannucchi, M. D., Jean Jacques Kiladjian, et al. / /N engl j med. - january 2015. - Vol. 29. P. 426-435.

Alvarez-Larran A., Pereira A., Cervantes F. et al. Assessment and prognostic value of the European LeukemiaNet criteria for clinicohematologic response, resistance, and intolerance to hydroxyurea in polycythemia vera // Blood. 2012. - Vol. 119. P. 1363-1369.

Barbui T, Barosi G, Birgegard G. et al; European LeukemiaNet. Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet // J Clin Oncol. 2011. - Vol. 29. P 761-770.

Barosi G, Birgegard G, Finazzi G. et al. A unified definition of clinical resistance and intolerance to hydroxycarbamide in polycythaemia vera and primary myelofibrosis: results of a European Leukemia-Net (ELN) consensus process // Br J Haematol. - 2010. - Vol. 148. P. 961-963.

Baxter EJ, Scott LM, Campbell PJ. et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders // Lancet. 2005. - Vol. 365. P. 1054-1061.

Bjorn M. E., deStricker K., Kjær L. et al. Combination Therapy with interferon and JAK1-2 inhibitor is feasible:Proof of concept with rapid reduction in JAK2V617F-alleleburden in polycythemia vera // Leukemia Research Reports. 2014. - Vol. 3. P. 73-75.

Cho S. Y., Xu M., Roboz J. et al. The Effect of CXCL12 Processing on CD34+ Cell Migration in Myeloproliferative Neoplasms // Cancer Research. 2010. - Vol. 70 (8). P. 3402-3410.

Cools J., Peeters P., Voet T. et al. Genomic organization of human JAK2 and mutation analysis of its JH2-domain in leukemia // Cytogenetic and Genome Research. 1999. - Vol. 85(3-4). P. 260-266.

Dameshek W. Some speculations on the myeloproliferative syndromes // Blood. 1951. - Vol. 6. - P. 372-375.

Elliott M. A., Tefferi A. Thrombosis and haemorrhage in polycythaemia vera and essential thrombocythaemia. British Journal of Haematology. 2005. - Vol. 128 (3). P. 275-290.

Fabio P. S. Santos, Srdan Verstovsek. JAK2 Inhibitors: Are They the Solution? // Clinical Lymphoma, Myeloma & Leukemia. - 2001. Vol. 11. No. S1. - P. 28-36.

Feener E. P., Rosario F., Dunn S. L. et al. Tyrosine Phosphorylation of Jak2 in the JH2 Domain Inhibits Cytokine Signaling // Molecular and Cellular Biology. 2004. P. 4968-4978.

Geron I, Abrahamsson AE, Barroga CF. et al. Selective inhibition of JAK2-driven erythroid differentiation of polycythemia vera progenitors // Cancer Cell. 2008. - Vol. 13. P. 321-330.

Goh KC, Ong WC, Hu C, et al. SB1518: A potent and orally active JAK2 inhibitor the treatment of myeloproliferative disorders [abstract] // Blood. - 2007. - P. 110.

http://www.fda.gov/NewsEvents/Newsroom/PressAn-nouncements/ucm425677.htm. [электронный ресурс] (дата обращения 29. 01. 2015).

James C., Ugo V., Le Couedic J. -P. et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera // Nature. 2005. Vol. 434. P. 1144-1148.

Kim J, Wessling-Resnick M. Iron and mechanisms of emotional behavior // J Nutr Biochem. 2014. - P. 25.

Kralovics R., Teo S. -S., Buser A. S. et al. Altered gene expression in myeloproliferative disorders correlates with activation of signaling by the V617F mutation of Jak2. - 2005. Vol. 106. P. 3374-3376.

Kralovics R, Passamonti F, Buser AS, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders // N Engl J Med. 2005. - Vol. 352. P. 1779-1790.

Lasho T. L., Pardanani A., Tefferi A. LNK Mutations in JAK2 Mutation-Negative Erythrocytosis // New England Journal of Medicine. 2010. - Vol. 363. P. 1189-1190.

Levine R. L., Wadleigh R., Cools J. et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis // Cancer Cell. 7p. P. 387-397.

Lu X., Levine R., Tong W. et al. Expression of a homodimeric type I cytokine receptor is required for JAK2V617F-mediated transformation// Proceedings of the National Academy of Sciences of the United States of America. 2005. - Vol. 102,09 (52). - P. 18962-18967.

Marchioli R., Finazzi G., Specchia G. et al. Cardiovascular Events and Intensity of Treatment in Polycythemia Vera // New England Journal of Medicine. 2013. - Vol. 368 (1). P. 22-33.

Massa M., Rosti V., Ramajoli I. et al. Circulating CD34+, CD133+, and Vascular Endothelial Growth Factor Receptor 2-Positive Endothelial Progenitor Cells in Myelofibrosis With Myeloid Metaplasia // Journal of Clinical Oncology. 2005. - Vol. 23 (24). P. 5688-5695.

Passamonti F., Elena C., Schnittger S. et al. Molecular and clinical features of the myeloproliferative neoplasm associated with JAK2 exon 12 mutations // Blood. 2011. - Vol. 117. P. 2813-2816.

Prchal JT, Gordeuk VR. Treatment target in poly-cythemia vera // N Engl J Med. 2013. - Vol. 368. P. 1555-1556.

Schmitt Alain J. H., Guichard J., Wendling F. et al. Pathologic interaction between megakaryocytes and polymorphonuclear leukocytes in myelofibrosis // Blood. 2000. - Vol. 96. P. 1342-1347.

Scott L. M., Tong W., Levine R. L. et al. JAK2 Exon 12 Mutations in Polycythemia Vera and Idiopathic Erythrocytosis // New England Journal of Medicinem. - 2007. - Vol. 356 (5). P. 459-468.

Shikhbabaeva D., Shuvaev V., Martynkevich I. et al. Polycythemia Vera Analysis of Diagnostic and Treatment Results on Population Level // ELN Frontiers Meeting. -2014. Berlin, Germany. P. 36.

Silvennoinen O., Ihle J. N., Schlessinger J. et al., Interferon-induced nuclear signalling by Jak protein tyrosine kinases // Nature 1993. - Vol. 366 (6455). P. 583-585.

Silver RT. Long-term effects of the treatment of polycythemia vera with recombinant interferon-alpha // Cancer. 2006. - Vol. 107. P. 451-458.

Suessmuth Y, Elliott J., Percy M. J. et al. A new poly-cythaemia vera-associated SOCS3 SH2 mutant (SOC-S3F136L) cannot regulate erythropoietin responses // British Journal of Haematology. 2009. - Vol. 147 (4). P. 450-458.

Tefferi A. Pathogenesis of Myelofibrosis With Myeloid Metaplasia // Journal of Clinical Oncology. 2005, Vol. 23(33). P. 8520-8530.

Tefferi A., Thiele J., Orazi A. et al. Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel // Blood 2007. - Vol. 110 (4). P. 1092-1097.

Tefferi A., Vardiman J. W. Classification and diagnosis of myeloproliferative neoplasms: The 2008 World Health Organization criteria and point-of-care diagnostic algorithms // Leukemia. 2007. - Vol. 22 (1). P. 14-22.

Tefferi A. Polycythemia vera and essential thrombocythe-mia: 2013 update on diagnosis, risk-stratification, and management // American Journal of Hematology. - 2013. - Vol. 88 (6). - P. 507-516.

Tobiasson M, Alyass B, Söderlund S, Birgegard G. High prevalence of restless legs syndrome among patients with polycythemia vera treated with venesectio // Med Oncol. - 2010. - Vol. 27, P. 105-107.

Vannucchi A. M., Guglielmelli P. Molecular pathophysiology of Philadelphia-negative myeloproliferative disorders: beyond JAK2 and MPL mutations // Haematologica. - 2008. - Vol. 93 (7). - P. 972-976.

Vannucchi A. et al. EHA 2014. Ruxolitinib Proves Superior to Best Available Therapy in a Prospective, Randomized, Phase 3 Study (RESPONSE) in Patients With Polycythemia Vera Resistant to or Intolerant of Hydroxyurea. - Abst. - LB2436

Vardiman J. W., Harris N. L., Brunning R. D. The World Health Organization (WHO) classification of the myeloid neoplasms. -2002. Vol. 100. - P. 2292-2302.

Verstovsek S., Kiladjian J. -J., Griesshammer M., Masszi T. Results of a prospective, randomized, open-label phase

study of ruxolitinib (RUX) in polycythemia vera (PV) patients resistant to or intolerant of hydroxyurea (HU): the RESPONSE trial // J Clin Oncol. - 2014. - Vol. 32 (5s). - abstr. P. 7026.

Wernig G, Kharas MG, Okabe R. et al. Efficacy of TG101348, a selective JAK2 inhibitor, in treatment of a murine model of JAK2V617F-induced polycythemia vera // Cancer Cell. 2008. - Vol. 13. - P. 311-320.

Zhou Y. -J., Chen M., Cusack N. A. et al. Unexpected Effects of FERM Domain Mutations on Catalytic Activity of Jak3 // Molecular Cell. Vol. 8. - P. 959-969.

Лицензия Creative Commons

Это произведение доступно по лицензии Creative Commons «Attribution-NonCommercial-NoDerivatives» («Атрибуция — Некоммерческое использование — Без производных произведений») 4.0 Всемирная.